160 related articles for article (PubMed ID: 21409498)
41. Feasibility of MR-only proton dose calculations for prostate cancer radiotherapy using a commercial pseudo-CT generation method.
Maspero M; van den Berg CAT; Landry G; Belka C; Parodi K; Seevinck PR; Raaymakers BW; Kurz C
Phys Med Biol; 2017 Nov; 62(24):9159-9176. PubMed ID: 29076458
[TBL] [Abstract][Full Text] [Related]
42. Image-based electronic patient records for secured collaborative medical applications.
Zhang J; Sun J; Yang Y; Liang C; Yao Y; Cai W; Jin J; Zhang G; Sun K
Conf Proc IEEE Eng Med Biol Soc; 2005; 2005():3218-20. PubMed ID: 17282930
[TBL] [Abstract][Full Text] [Related]
43. Analysis of outcomes in radiation oncology: an integrated computational platform.
Liu D; Ajlouni M; Jin JY; Ryu S; Siddiqui F; Patel A; Movsas B; Chetty IJ
Med Phys; 2009 May; 36(5):1680-9. PubMed ID: 19544785
[TBL] [Abstract][Full Text] [Related]
44. MRI-based IMPT planning for prostate cancer.
Depauw N; Keyriläinen J; Suilamo S; Warner L; Bzdusek K; Olsen C; Kooy H
Radiother Oncol; 2020 Mar; 144():79-85. PubMed ID: 31734604
[TBL] [Abstract][Full Text] [Related]
45. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
46. Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy.
Saito M; Suzuki T; Sugama Y; Marino K; Sano N; Komiyama T; Aoki S; Maehata Y; Yoshizawa K; Ashizawa K; Suzuki H; Ueda K; Miyasaka Y; Araya M; Takahashi H; Onishi H
J Radiat Res; 2020 May; 61(3):487-493. PubMed ID: 32211861
[TBL] [Abstract][Full Text] [Related]
47. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy.
Pedersen J; Flampouri S; Bryant C; Liang X; Mendenhall N; Li Z; Liu M; Muren LP
Radiother Oncol; 2020 Jan; 142():253-260. PubMed ID: 31630864
[TBL] [Abstract][Full Text] [Related]
48. Technical note: electronic chart checks in a paperless radiation therapy clinic.
Yang D; Wu Y; Brame RS; Yaddanapudi S; Rangaraj D; Li HH; Goddu SM; Mutic S
Med Phys; 2012 Aug; 39(8):4726-32. PubMed ID: 22894397
[TBL] [Abstract][Full Text] [Related]
49. Benchmarking of a treatment planning system for spot scanning proton therapy: comparison and analysis of robustness to setup errors of photon IMRT and proton SFUD treatment plans of base of skull meningioma.
Harding R; Trnková P; Weston SJ; Lilley J; Thompson CM; Short SC; Loughrey C; Cosgrove VP; Lomax AJ; Thwaites DI
Med Phys; 2014 Nov; 41(11):111710. PubMed ID: 25370624
[TBL] [Abstract][Full Text] [Related]
50. Particle therapy tumour outcomes: An updated systematic review.
Hwang EJ; Gorayski P; Le H; Hanna GG; Kenny L; Penniment M; Buck J; Thwaites D; Ahern V
J Med Imaging Radiat Oncol; 2020 Oct; 64(5):711-724. PubMed ID: 32270626
[TBL] [Abstract][Full Text] [Related]
51. Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
Antico M; Prinsen P; Cellini F; Fracassi A; Isola AA; Cobben D; Fontanarosa D
PLoS One; 2019; 14(2):e0213002. PubMed ID: 30818345
[TBL] [Abstract][Full Text] [Related]
52. Independent dose verification system with Monte Carlo simulations using TOPAS for passive scattering proton therapy at the National Cancer Center in Korea.
Shin WG; Testa M; Kim HS; Jeong JH; Lee SB; Kim YJ; Min CH
Phys Med Biol; 2017 Sep; 62(19):7598-7616. PubMed ID: 28809759
[TBL] [Abstract][Full Text] [Related]
53. Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization.
Kurz C; Süss P; Arnsmeyer C; Haehnle J; Teichert K; Landry G; Hofmaier J; Exner F; Hille L; Kamp F; Thieke C; Ganswindt U; Valentini C; Hölscher T; Troost E; Krause M; Belka C; Küfer KH; Parodi K; Richter C
Z Med Phys; 2019 Aug; 29(3):216-228. PubMed ID: 30409729
[TBL] [Abstract][Full Text] [Related]
54. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations.
Moteabbed M; Trofimov A; Sharp GC; Wang Y; Zietman AL; Efstathiou JA; Lu HM
Phys Med Biol; 2017 Mar; 62(5):1644-1660. PubMed ID: 28166057
[TBL] [Abstract][Full Text] [Related]
55. DICOM for quantitative imaging biomarker development: a standards based approach to sharing clinical data and structured PET/CT analysis results in head and neck cancer research.
Fedorov A; Clunie D; Ulrich E; Bauer C; Wahle A; Brown B; Onken M; Riesmeier J; Pieper S; Kikinis R; Buatti J; Beichel RR
PeerJ; 2016; 4():e2057. PubMed ID: 27257542
[TBL] [Abstract][Full Text] [Related]
56. A light-weight compact proton gantry design with a novel dose delivery system for broad-energetic laser-accelerated beams.
Masood U; Cowan TE; Enghardt W; Hofmann KM; Karsch L; Kroll F; Schramm U; Wilkens JJ; Pawelke J
Phys Med Biol; 2017 Jul; 62(13):5531-5555. PubMed ID: 28609301
[TBL] [Abstract][Full Text] [Related]
57. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy.
Underwood T; Giantsoudi D; Moteabbed M; Zietman A; Efstathiou J; Paganetti H; Lu HM
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):454-464. PubMed ID: 27084660
[TBL] [Abstract][Full Text] [Related]
58. An integrated Monte Carlo dosimetric verification system for radiotherapy treatment planning.
Yamamoto T; Mizowaki T; Miyabe Y; Takegawa H; Narita Y; Yano S; Nagata Y; Teshima T; Hiraoka M
Phys Med Biol; 2007 Apr; 52(7):1991-2008. PubMed ID: 17374923
[TBL] [Abstract][Full Text] [Related]
59. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses.
Quigley MM; Mate TP; Sylvester JE
Urol Oncol; 2009; 27(5):473-82. PubMed ID: 18625565
[TBL] [Abstract][Full Text] [Related]
60. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes.
Kubeš J; Haas A; Vondráček V; Andrlík M; Navrátil M; Sláviková S; Vítek P; Dědečková K; Prausová J; Ondrová B; Vinakurau Š; Grebenyuk A; Doležal T; Velacková B; Rosina J
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1090-1097. PubMed ID: 33587990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
